Innovatit Seafood Systems, LLC v. Commissioner for Patents

573 F. Supp. 2d 96, 2008 U.S. Dist. LEXIS 66364
CourtDistrict Court, District of Columbia
DecidedAugust 29, 2008
DocketCivil Action 06-0822 (JR), 06-0825(JR)
StatusPublished

This text of 573 F. Supp. 2d 96 (Innovatit Seafood Systems, LLC v. Commissioner for Patents) is published on Counsel Stack Legal Research, covering District Court, District of Columbia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Innovatit Seafood Systems, LLC v. Commissioner for Patents, 573 F. Supp. 2d 96, 2008 U.S. Dist. LEXIS 66364 (D.D.C. 2008).

Opinion

MEMORANDUM

JAMES ROBERTSON, District Judge.

Inventor Earnest A. Voisin of Innovatit Seafood discovered that subjecting shellfish to high pressure can rid them of harmful pathogens without cooking them. Voisin applied for a patent on his pressure-pasteurization process (the '725 application), as well as for the product that this process produced (the '704 application). The patent examiner rejected both applications. It seems that, although the pasteurization achieved by Voisin’s method of applying pressure to shellfish is novel, the idea of applying pressure to shellfish, and a process for producing a pasteurized, shucked oyster, are not. A Japanese patent to Yasushi (JP '156) teaches mollusk pressurization as a means of relaxing the adductor muscle and shucking the shellfish, and a U.S. patent issued to Tesvieh (the '064 patent) produces an oyster that is pasteurized and shucked. The first question presented in this case is whether the application of the old process to the new purpose, without any meaningful change in the procedure, is patentable over the Japanese reference. The second question is whether a product is patentable if disclosed by an earlier reference to a different process. The answer to both questions is No.

Standard of Review

These cases arise under 35 U.S.C. § 145, which authorizes a patent applicant to sue for a patent in this district when “dissatisfied” with the final decision *99 of the Board of Patent Appeals and Interferences. 1 In such a suit, the PTO is treated as an administrative agency and its decisions are afforded the deference that other agencies receive when adjudicating facts within their zone of competence. See Mazzari v. Rogan, 323 F.3d 1000, 1004-05 (Fed.Cir.2003). Findings of fact are subject to the “substantial evidence” standard. Id. at 1005. Under the Federal Circuit’s somewhat elusive precedents, anticipation is regarded as a question of fact, see In re Schreiber, 128 F.3d 1473, 1477 (Fed.Cir.1997), while obviousness is regarded as “a question of law based on underlying findings of fact.” In re Gartside, 203 F.3d 1305, 1316 (Fed.Cir.2000). In short, the presumption is that the technical expertise of the PTO and the Board is entitled to substantial deference — its finding of anticipation will be upheld if there is substantial evidence in the record to support it, and its finding of obviousness will be affirmed if appropriate based on its own findings of fact regarding the state of the art.

No. 06-0822 — The '725 Process Patent Claim

1) Anticipation as to Claims 6 and 27

The applicable standard of review drives the answers to many of the preliminary arguments that Innovatit raises in attempting to refute the PTO’s finding that Claims 6 and 27 of its patent application are anticipated by the Japanese reference. A finding of anticipation under 35 U.S.C. § 102 “requires that all of the elements and limitations of the claimed subject matter must be expressly or inherently described in a single prior art reference.” Elan Pharm. Inc., v. Mayo Found., 304 F.3d 1221, 1227 (Fed.Cir.2002). Innovatit claims that its patent contains two limitations different from JP '156: (1) it discloses a different range of times and pressures for the prescribed mollusk pressurization, and (2) it teaches doing the process at ambient temperature, whereas JP '156 is silent as to temperature. There is substantial evidence in the record to support the Board’s conclusion that these limitations do not distinguish the '725 application from the Japanese reference.

First, the time-pressure envelope disclosed by JP '156 is covered almost entirely by the range taught in Innovatit’s application. See [25] at 15, fig. 1, for a helpful visual display. While the Federal Circuit has declined to find anticipation in cases of very slight overlap, see Atofina v. Great Lakes Chem. Corp., 441 F.3d 991, 1000 (Fed.Cir.2006), it has routinely found anticipation where a claimed range substantially overlaps with ranges disclosed in the prior art. See, e.g., Perricone v. Medicis Pharm. Corp., 432 F.3d 1368, 1377 (Fed. Cir.2005); Atlas Powder Co. v. Ireco, Inc., 190 F.3d 1342, 1345 (Fed.Cir.1999); Titanium Metals Corp. v. Banner, 778 F.2d 775, 781 (Fed.Cir.1985). Moreover, the holding in Atofina was expressly predicated on the fact that the prior art reference did not disclose any point in particular that would be encompassed by the range claimed in the application. See 441 F.3d at 1000 (“The disclosure is only that of a range, not a specific temperature in that range.”). Here, it is beyond dispute that the range claimed by Innovatit’s application encompasses not only the vast majority of the range claimed in JP '156, but also the particular pressure-time value taught in its specific embodiment. Deference is due to the PTO’s conclusion that the range claimed by Innovatit is anticipated in light of its overlap with the range in the prior *100 art, and that conclusion is supported by more than substantial evidence.

Innovatit also argues that it limits its process by requiring that it be conducted “without application of heat,” a claim limitation absent from JP '156. But such a “negative limitation,” — an instruction in the patent not to do something— has only limited power to bring novelty to an otherwise anticipated patent. See Upsher-Smith Labs., Inc. v. Pamlab, 412 F.3d 1319, 1322 (Fed.Cir.2005) (a patent that optionally includes a step can anticipate a patent that specifically excludes it). Novelty is not created by a negative limitation where one skilled in the art would have read the prior art reference to exclude the relevant step. Cf. In re Baxter Travenol Labs., 952 F.2d 388, 390-91 (Fed. Cir.1991).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Peters v. Active Manufacturing Co.
129 U.S. 530 (Supreme Court, 1889)
Atofina v. Great Lakes Chemical Corporation
441 F.3d 991 (Federal Circuit, 2006)
Upsher-Smith Laboratories, Inc. v. Pamlab, L.L.C.
412 F.3d 1319 (Federal Circuit, 2005)
In Re Donald H. Thorpe
777 F.2d 695 (Federal Circuit, 1985)
In Re Baxter Travenol Labs
952 F.2d 388 (Federal Circuit, 1991)
In Re Schreiber
128 F.3d 1473 (Federal Circuit, 1997)
In Re Robert J. Gartside and Richard C. Norton
203 F.3d 1305 (Federal Circuit, 2000)
In Re Cruciferous Sprout Litigation
301 F.3d 1343 (Federal Circuit, 2002)
Application of Benner
174 F.2d 938 (Customs and Patent Appeals, 1949)

Cite This Page — Counsel Stack

Bluebook (online)
573 F. Supp. 2d 96, 2008 U.S. Dist. LEXIS 66364, Counsel Stack Legal Research, https://law.counselstack.com/opinion/innovatit-seafood-systems-llc-v-commissioner-for-patents-dcd-2008.